Allergan says phase 2 data showed some differentiation between DARPin, Lucentis

Says DARPin safety data made company "comfortable" in doing more phase 2 work. Says company has completed initial analyses and second stage of Phase 2 is still ongoing. Says plan is for existing Phase 2 study to have three stages.

View Comments (0)